author-photo

Makoto Tahara

University of Tokyo

99

Papers

1202

Citations

Citation Trend

Filter By

Papers (66) Sort By

Journal Conference Others

Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer

2019 International Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer

2019 Future Oncology
Show All
- Source
- Cite
- Save
Citations (53)
Clinical impact of cachexia in unresectable locally advanced head and neck cancer: supplementary analysis of a phase II trial (JCOG0706-S2)

2019 Japanese Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer

2019 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (42)
Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK

2018 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (11)
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (16)
Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally BID to patients with advanced solid tumors.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation

2017 Oncotarget
Show All
- Source
- Cite
- Save
Citations (9)